Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases.
about
Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: recent advances and controversiesSurvival Impact of Early Post-Transplant Toxicities in Pediatric and Adolescent Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Malignant and Nonmalignant Diseases: Recognizing Risks and Optimizing OutcomesAn intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.Long-Term Stable Mixed Chimerism after Hematopoietic Stem Cell Transplantation in Patients with Non-Malignant Disease, Shall We Be Tolerant?Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying DiseaseCardiac QTc interval characteristics before and after hematopoietic stem cell transplantation: an analysis of 995 consecutive patients at a single center.Non-myeloablative allogeneic hematopoietic stem cell transplantation.Alternative haematopoietic stem cell sources for transplantation: place of umbilical cord blood.High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation.Reduced-intensity conditioning for allogeneic stem cell transplant in primary immune deficiencies.Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.Stem cell transplantation for the treatment of immunodeficiency in children: current status and hopes for the future.Reduced intensity transplantation for primary immunodeficiency disorders.Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP.Long-term outcomes of fludarabine, melphalan and antithymocyte globulin as reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency disorders: a prospective single centerHematopoietic stem cell transplantation in relapsed ALK+ anaplastic large cell lymphoma in children and adolescents: a study on behalf of the SFCE and SFGM-TC.Chronic granulomatous disease-haematopoietic stem cell transplantation versus conventional treatment.Reduced-intensity conditioning followed by allogeneic transplantation in pediatric malignancies: a report from the Société Française des Cancers de l'Enfant and the Société Française de Greffe de Moelle et de Thérapie Cellulaire.Reduced-toxicity alternate-donor stem cell transplantation with posttransplant cyclophosphamide for primary immunodeficiency disorders.Pediatric allo-SCT for malignant and non-malignant diseases: impact on health-related quality of life outcomes.Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation.Molecular diagnosis of severe combined immunodeficiency--identification of IL2RG, JAK3, IL7R, DCLRE1C, RAG1, and RAG2 mutations in a cohort of Chinese and Southeast Asian children.Bone marrow transplantation in Schimke immuno-osseous dysplasia
P2860
Q26784285-580785F3-79C3-4FB5-8CC6-669810500CACQ33870341-7F88D544-93E4-4FE1-B156-B4F5EC5AD2BDQ34206291-B5ED899B-2D0E-4292-93B6-EB90BFD729DDQ36010605-B5195DAA-B5C8-412D-B377-8B12E3E1DC8DQ36156205-7B364C0A-8E13-40E1-BBA9-3DDAEE424169Q36543654-A52CC1D6-D96B-4B60-B009-C256B501481EQ37308127-886BF74C-B595-4B81-B73F-0667E83DF45EQ37435417-053B3098-C208-42B1-908D-D2947A3428E3Q37788219-992AB0CA-1F06-40C6-86EA-113D45A3D5B4Q37990549-B5FCFCFC-82D5-4735-B22B-5424D93D360DQ38664909-C60BE2DE-7FAF-48CF-993F-54022BF27CECQ38735833-6FA5D4CB-4EA7-40F8-B2F2-486DABE76782Q38912369-D5604388-9314-45E5-A64A-A64E20CA8251Q39049336-F6AFDCC4-6F79-4484-9700-676F95B0C7C5Q41106225-34A9EAF0-AD71-4495-974E-080B731511E1Q41141389-9842202F-94CB-4110-AF66-FA56F8E912B8Q45391987-BEA31A2F-C53A-4A19-8182-CFF9AD5C2572Q46120530-391BE1D3-E7C1-443C-9F6B-DA5011D50B15Q47810837-A856D50C-6CE7-4094-9712-397F34F9F0C2Q48352335-50EBFAF0-FFCC-4F2E-894D-089D4675790AQ50790158-7584F7BB-9964-4CD4-9144-E21F17D8DA7CQ54624587-F189BD3E-0612-4BAA-865E-853641FC46B0Q57756339-157FD99E-2BEF-4147-8235-2B13FA1947A2
P2860
Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Reduced intensity conditioning ...... ant and nonmalignant diseases.
@en
Reduced intensity conditioning ...... ant and nonmalignant diseases.
@nl
type
label
Reduced intensity conditioning ...... ant and nonmalignant diseases.
@en
Reduced intensity conditioning ...... ant and nonmalignant diseases.
@nl
prefLabel
Reduced intensity conditioning ...... ant and nonmalignant diseases.
@en
Reduced intensity conditioning ...... ant and nonmalignant diseases.
@nl
P2093
P2860
P356
P1476
Reduced intensity conditioning ...... ant and nonmalignant diseases.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BMT.1705923
P407
P577
2007-11-26T00:00:00Z